[
  {
    "ts": "2026-02-10T12:00:00+00:00",
    "headline": "Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy",
    "summary": "36 abstracts to be presented across Regeneron-invented therapies, including first-time Phase 3 presentations for two distinct investigational allergen-blocking antibodies for cat and birch allergies New Dupixent® (dupilumab) data highlight its clinical and real-world impact across dermatological, respiratory and gastrointestinal diseases, including analyses of food allergy sensitization in children with atopic dermatitis TARRYTOWN, N.Y., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceutical",
    "url": "https://finance.yahoo.com/news/regeneron-highlights-expanding-immunology-portfolio-120000302.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "c7e12ad7-9a93-31e8-908d-20989c450755",
      "content": {
        "id": "c7e12ad7-9a93-31e8-908d-20989c450755",
        "contentType": "STORY",
        "title": "Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy",
        "description": "",
        "summary": "36 abstracts to be presented across Regeneron-invented therapies, including first-time Phase 3 presentations for two distinct investigational allergen-blocking antibodies for cat and birch allergies New Dupixent® (dupilumab) data highlight its clinical and real-world impact across dermatological, respiratory and gastrointestinal diseases, including analyses of food allergy sensitization in children with atopic dermatitis TARRYTOWN, N.Y., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceutical",
        "pubDate": "2026-02-10T12:00:00Z",
        "displayTime": "2026-02-10T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142",
          "originalWidth": 800,
          "originalHeight": 126,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ohIVokMiKClSVTQVwyB2lw--~B/aD0xMjY7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142.cf.webp",
              "width": 800,
              "height": 126,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YuYzNeQcIK6rRYN1HdT6UA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-highlights-expanding-immunology-portfolio-120000302.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-highlights-expanding-immunology-portfolio-120000302.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-10T14:07:00+00:00",
    "headline": "Evommune Nearly Doubles — Has Dupixent Met Its Match In Eczema?",
    "summary": "IPO stock Evommune roughly doubled Tuesday on positive results for its intravenously infused eczema treatment.",
    "url": "https://www.investors.com/news/technology/ipo-stock-evommune-eczema-treatment-dupixent/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "a9b9294f-23e5-3026-86bc-0ac62329f349",
      "content": {
        "id": "a9b9294f-23e5-3026-86bc-0ac62329f349",
        "contentType": "STORY",
        "title": "Evommune Nearly Doubles — Has Dupixent Met Its Match In Eczema?",
        "description": "",
        "summary": "IPO stock Evommune roughly doubled Tuesday on positive results for its intravenously infused eczema treatment.",
        "pubDate": "2026-02-10T14:07:00Z",
        "displayTime": "2026-02-10T14:07:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/a9b9294f-23e5-3026-86bc-0ac62329f349/evommune-nearly-doubles-%E2%80%94-has.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/3652e8fd1d923e69f18c6199c0c5e598",
          "originalWidth": 1000,
          "originalHeight": 565,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Lt9IGhALNTBIXpG4YttIrw--~B/aD01NjU7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/3652e8fd1d923e69f18c6199c0c5e598.cf.webp",
              "width": 1000,
              "height": 565,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6k_EDAg9lkX1tourz9JiKQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/3652e8fd1d923e69f18c6199c0c5e598.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/ipo-stock-evommune-eczema-treatment-dupixent/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "SNY"
            },
            {
              "symbol": "SNYNF"
            },
            {
              "symbol": "EVMN"
            },
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-10T17:42:12+00:00",
    "headline": "Has Dupixent Met Its Match? Rivals Nektar, Evommune Catapult On Eczema Results.",
    "summary": "Biotech stocks Nektar Therapeutics and Evommune launched Tuesday on positive results for their eczema treatments.",
    "url": "https://www.investors.com/news/technology/ipo-stock-evommune-eczema-treatment-dupixent/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "a9b9294f-23e5-3026-86bc-0ac62329f349",
      "content": {
        "id": "a9b9294f-23e5-3026-86bc-0ac62329f349",
        "contentType": "STORY",
        "title": "Has Dupixent Met Its Match? Rivals Nektar, Evommune Catapult On Eczema Results.",
        "description": "",
        "summary": "Biotech stocks Nektar Therapeutics and Evommune launched Tuesday on positive results for their eczema treatments.",
        "pubDate": "2026-02-10T17:42:12Z",
        "displayTime": "2026-02-10T17:42:12Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/a9b9294f-23e5-3026-86bc-0ac62329f349/has-dupixent-met-its-match-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/3652e8fd1d923e69f18c6199c0c5e598",
          "originalWidth": 1000,
          "originalHeight": 565,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Lt9IGhALNTBIXpG4YttIrw--~B/aD01NjU7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/3652e8fd1d923e69f18c6199c0c5e598.cf.webp",
              "width": 1000,
              "height": 565,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6k_EDAg9lkX1tourz9JiKQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/3652e8fd1d923e69f18c6199c0c5e598.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/ipo-stock-evommune-eczema-treatment-dupixent/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "EVMN"
            },
            {
              "symbol": "REGN"
            },
            {
              "symbol": "SNY"
            },
            {
              "symbol": "SNYNF"
            },
            {
              "symbol": "NKTR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-10T16:57:55+00:00",
    "headline": "Regeneron Pipeline Progress Continues but Near-Term Visibility Remains Limited, RBC Says",
    "summary": "Regeneron Pharmaceuticals' (REGN) long-term prospects seem promising but there is still a lack of cl",
    "url": "https://finance.yahoo.com/news/regeneron-pipeline-progress-continues-near-165755981.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "6c6361cd-78fa-3a69-91b9-51cd04253fbe",
      "content": {
        "id": "6c6361cd-78fa-3a69-91b9-51cd04253fbe",
        "contentType": "STORY",
        "title": "Regeneron Pipeline Progress Continues but Near-Term Visibility Remains Limited, RBC Says",
        "description": "",
        "summary": "Regeneron Pharmaceuticals' (REGN) long-term prospects seem promising but there is still a lack of cl",
        "pubDate": "2026-02-10T16:57:55Z",
        "displayTime": "2026-02-10T16:57:55Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-pipeline-progress-continues-near-165755981.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-pipeline-progress-continues-near-165755981.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            },
            {
              "symbol": "SNY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-10T12:13:00+00:00",
    "headline": "Nektar, continuing comeback, says eczema drug’s effects hold up in follow-up study",
    "summary": "The results vaulted Nektar’s market value to over $1 billion amid expectations the drug might prove a challenger to widely used medications like Dupixent.",
    "url": "https://www.biopharmadive.com/news/nektar-rezpegaldesleukin-eczema-maintenance-data-results/811806/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "6994b182-57ca-3e3a-b0ac-5726fb73a6f6",
      "content": {
        "id": "6994b182-57ca-3e3a-b0ac-5726fb73a6f6",
        "contentType": "STORY",
        "title": "Nektar, continuing comeback, says eczema drug’s effects hold up in follow-up study",
        "description": "",
        "summary": "The results vaulted Nektar’s market value to over $1 billion amid expectations the drug might prove a challenger to widely used medications like Dupixent.",
        "pubDate": "2026-02-10T12:13:00Z",
        "displayTime": "2026-02-10T12:13:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/ab0100ff22dcd604e28e26f63b7e28a0",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5v2gYUHyJ1AR46sVYpqIHA--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/ab0100ff22dcd604e28e26f63b7e28a0.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dkwf9lKXNHro10yfUo.ahA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/ab0100ff22dcd604e28e26f63b7e28a0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/nektar-rezpegaldesleukin-eczema-maintenance-data-results/811806/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/nektar-continuing-comeback-says-eczema-121300710.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NKTR"
            },
            {
              "symbol": "REGN"
            },
            {
              "symbol": "SNY"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]